News

Based on research by Dr Thomas Tuschl, a founder of Alnylam, the newly allowed claims broadly cover methods of making siRNAs for any target, with or without chemical

Although the bacteria has only been tested in a lab dish, HIV specialist Bharat Ramratnam and his colleagues from Brown Medical School assert that a modified version of

The company believes this significantly strengthens its intellectual property platform in order to develop and ultimately commercialize ZIO-101. “We are thrilled to have a very strong patent position

The Shanghai Institutes for Biological Sciences (SIBS) initial human clinical trial results indicate that T cell vaccination induces immune responses that correlate with reductions in joint swelling, tenderness,

Under the terms of the agreement, which is valid until the end of 2008, ChemGenex will receive a total retainer fee of approximately A$1 million, with potential additional

The terms of this expanded agreement include Squire making an up-front payment, providing on-going royalties on the sale of Pennsaid and making an investment of $500,000 in Nuvo.

The companies aim to jointly identify and develop pre-clinical development candidates suitable for future selection as drug candidates for clinical testing. While the original contract was exclusively targeted

The potential vaccine will be based on Tripep’s proprietary hepatitis C virus (HCV) antigen and delivered to infected individuals using Inovio’s medpulser DNA delivery system. Initiation of a

In order to achieve the milestone 4SC applied its proprietary virtual high throughput screening technology, 4Scan, to identify active agents against specific targets provided by Sanwa Kagaku Kenkyusho